ICLR Stock Analysis: ICON | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 12.693m USD | 12M Return: 4% | IE0005711209 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 127M
EPS Trend: -56.4%
Qual. Beats: 0
Rev. Trend: 37.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICON Public Limited Company (ICLR) is a Dublin-headquartered clinical research organization (CRO) that provides outsourced drug and medical device development services to pharmaceutical, biotechnology, and medical device companies, as well as government and public health organizations. Founded in 1989 and listed on NASDAQ since 1998, ICON operates across Ireland, the rest of Europe, the United States, and other international markets, supporting clients from compound selection through Phase I–IV clinical studies, as well as peri- and post-approval work, data solutions, and site and patient access services. Its offerings span clinical trial management, consulting, contract staffing, commercial strategy and post-market commercialization, and a broad laboratory services portfolio that includes bioanalytical, biomarker, vaccine, good manufacturing practice (GMP), and central laboratory capabilities, delivered through both full-service and functional service partnership models. The company also provides specialized solutions such as adaptive trials, cardiac safety, decentralized and hybrid clinical trials, medical imaging, real-world intelligence, and language services, and maintains a strategic alliance with Advarra to build a connected, research-ready clinical trial site network.
CROs like ICON act as external development partners for drug and device sponsors, managing the operational, regulatory, and data aspects of clinical programs so clients can focus resources on discovery and commercialization. The industrys growth has been supported in recent years by rising R&D outsourcing rates among large pharma, increased clinical trial complexity, and the expansion of decentralized and hybrid trial designs.
- Biotech funding weakness pressures clinical trial bookings
- Lab services margins expand on biomarker and vaccine demand
- Medpace competition intensifies in small-mid biotech segment
| Net Income: 69.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: -2.23% < 20% (prev 9.30%; Δ -11.53% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.09b > Net Income 69.5m |
| Net Debt (2.67b) to EBITDA (1.23b): 2.17 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.4m) vs 12m ago -2.73% < -2% |
| Gross Margin: 21.89% > 18% (prev 28.57%; Δ -6.68% > 0.5%) |
| Asset Turnover: 50.48% > 50% (prev 48.73%; Δ 1.75% > 0%) |
| Interest Coverage Ratio: 4.58 > 6 (EBIT TTM 857.2m / Interest Expense TTM 187.1m) |
| A: -0.01 (Total Current Assets 3.75b - Total Current Liabilities 3.93b) / Total Assets 16.4b |
| B: 0.14 (Retained Earnings 2.30b / Total Assets 16.4b) |
| C: 0.05 (EBIT TTM 857.2m / Avg Total Assets 16.5b) |
| D: 1.34 (Book Value of Equity 9.38b / Total Liabilities 7.02b) |
| Altman-Z'' = 2.13 = BBB |
| DSRI: 0.95 (Receivables 2.71b/2.78b, Revenue 8.33b/8.09b) |
| GMI: 1.31 (GM 28.57% / 21.89%) |
| AQI: 0.96 (AQ_t 0.74 / AQ_t-1 0.77) |
| SGI: 1.03 (Revenue 8.33b / 8.09b) |
| TATA: -0.06 (NI 69.5m - CFO 1.09b) / TA 16.4b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of August 11, 2026, the stock is trading at USD 166.05 with a total of 503,387 shares traded. Over the past week, the price has changed by +4.82%, over one month by -1.00%, over three months by +39.58% and over the past year by +3.97%.
Current recommended Stop Loss: 155.10 (which is 6.6% or 1.3 ATR below the current price).
ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.
- StrongBuy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 185.6 | 11.7% |
P/E Trailing = 249.2576
P/E Forward = 15.7978
P/S = 1.5303
P/B = 1.3534
P/EG = 0.5334
Revenue TTM = 8.33b USD
EBIT TTM = 857.2m USD
EBITDA TTM = 1.23b USD
Long Term Debt = 2.11b USD (from longTermDebt, last quarter)
Short Term Debt = 1.28b USD (from shortTermDebt, last quarter)
Debt = 3.60b USD (from shortLongTermDebtTotal, last quarter) + Leases 102.8m
Net Debt = 2.67b USD (calculated: Debt 3.60b - CCE 928.4m)
Enterprise Value = 15.4b USD (12.7b + Debt 3.60b - CCE 928.4m)
Interest Coverage Ratio = 4.58 (Ebit TTM 857.2m / Interest Expense TTM 187.1m)
EV/FCF = 17.10x (Enterprise Value 15.4b / FCF TTM 898.3m)
FCF Yield = 5.85% (FCF TTM 898.3m / Enterprise Value 15.4b)
FCF Margin = 10.78% (FCF TTM 898.3m / Revenue TTM 8.33b)
Net Margin = 0.83% (Net Income TTM 69.5m / Revenue TTM 8.33b)
Gross Margin = 21.89% ((Revenue TTM 8.33b - Cost of Revenue TTM 6.51b) / Revenue TTM)
Gross Margin QoQ = 18.83% (prev 23.50%)
Tobins Q-Ratio = 0.94 (Enterprise Value 15.4b / Total Assets 16.4b)
Interest Expense / Debt = 5.20% (Interest Expense 187.1m / Debt 3.60b)
Taxrate = 49.37% (67.8m / 137.4m)
NOPAT = 434.0m (EBIT 857.2m * (1 - 49.37%))
Current Ratio = 0.95 (Total Current Assets 3.75b / Total Current Liabilities 3.93b)
Debt / Equity = 0.38 (Debt 3.60b / totalStockholderEquity, last quarter 9.38b)
Debt / EBITDA = 2.17 (Net Debt 2.67b / EBITDA 1.23b)
Debt / FCF = 2.97 (Net Debt 2.67b / FCF TTM 898.3m)
Total Stockholder Equity = 9.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.42% (Net Income 69.5m / Total Assets 16.4b)
RoE = 0.75% (Net Income TTM 69.5m / Total Stockholder Equity 9.30b)
RoCE = 7.51% (EBIT 857.2m / Capital Employed (Equity 9.30b + L.T.Debt 2.11b))
RoIC = 3.26% (NOPAT 434.0m / Invested Capital 13.3b)
WACC = 7.33% (E(12.7b)/V(16.3b) * Re(8.66%) + D(3.60b)/V(16.3b) * Rd(5.20%) * (1-Tc(0.49)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.72 | Cagr: -3.20%
[DCF] Terminal Value 73.89% ; FCFF base≈940.3m ; Y1≈861.1m ; Y5≈758.7m
[DCF] Fair Price = 121.6 (EV 12.0b - Net Debt 2.67b = Equity 9.38b / Shares 77.2m; r=8.35% [WACC [floored]]; 5y FCF grow -10.46% → 2.50% )
EPS Correlation: -56.44 | EPS CAGR: -5.61% | SUE: 0.27 | # QB: 0
Revenue Correlation: 37.93 | Revenue CAGR: 0.55% | SUE: 0.62 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.67 | Chg30d=-1.24% | Revisions=-7% | Analysts=14
EPS current Year (2026-12-31): EPS=10.59 | Chg30d=-0.45% | Revisions=+82% | GrowthEPS=-15.5% | GrowthRev=-1.6%
EPS next Year (2027-12-31): EPS=11.87 | Chg30d=+0.12% | Revisions=+50% | GrowthEPS=+12.1% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: +51% (up=31, down=9)